Monte Rosa Therapeutics Sees Surge in Short Interest

Biotech firm's stock sees 21.7% increase in short positions in February

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company focused on accelerating drug discovery, saw a significant increase in short interest in February. As of February 13th, short interest totaled 9,330,612 shares, a 21.7% jump from the January 29th total of 7,664,016 shares. This represents approximately 15.3% of the company's outstanding stock. Based on the average daily trading volume of 1,005,178 shares, the current short interest ratio stands at 9.3 days.

Why it matters

The surge in short interest could indicate that some investors are betting against Monte Rosa Therapeutics' stock performance, potentially signaling concerns about the company's future prospects or the broader market conditions. Short selling activity is closely watched as it can provide insights into investor sentiment and potential volatility in a stock's price.

The details

Monte Rosa Therapeutics, headquartered in Cambridge, Massachusetts, is a biotechnology company that uses AI-driven discovery methods to pursue programs in immuno-oncology and neuroscience. The company has seen its stock price fluctuate in recent months, with shares trading between a 52-week low of $3.50 and a high of $25.77.

  • As of February 13th, 2026, short interest in Monte Rosa Therapeutics totaled 9,330,612 shares.
  • This represents a 21.7% increase from the January 29th, 2026 short interest total of 7,664,016 shares.

The players

Monte Rosa Therapeutics, Inc.

A biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest in Monte Rosa Therapeutics' stock could signal growing investor skepticism about the company's prospects, though the reasons behind the increased short positions are not entirely clear. Investors will likely continue to monitor the stock's performance and short interest activity for any further developments.